OrbiMed-led $80M series B to help Adicet bring its γδ cell therapies to the clinic

Adicet raised $80 million in an untranched series B round led by existing investor OrbiMed to bring its first three off-the-shelf γδ T cell therapies to the clinic.

The company plans to submit in six months an IND for its lead candidate -- an allogeneic γδ CD20 CAR T cell therapy -- to treat non-Hodgkin lymphoma...